Clinical Trial Update: Infliximab for the Prevention of Graft-versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports completion of a study evaluating infliximab for preventing graft-versus-host disease after allogeneic hematopoietic stem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Infliximab (infliximab)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Graft-Versus-Host Disease | Phase 2 | Status: COMPLETED